Corticosteroids are associated with increased survival in elderly presenting severe SARS-Cov2 infection
Gallay, L.; Tran, V.-T.; Perrodeau, E.; Vignier, N.; Mahevas, M.; Bisio, F.; Forestier, E.; Lescure, X.
Show abstract
ObjectiveTo assess the effectiveness of corticosteroids among elderly patients with COVID-19 pneumonia requiring oxygen. DesignComparative observational study based on routine care data. Baseline characteristics of patients were balanced using propensity-score inverse probability of treatment weighting. SettingGeriatric and infectious diseases wards from 36 hospitals in France and Luxembourg. ParticipantsAdults > 80 years old PCR confirmed SARS-CoV-2 infection or typical CT-scan images, requiring oxygen [≥] 3L/min and with an inflammatory syndrome (C-reactive protein [≥] 40mg/L). MeasurementsThe primary outcome was overall survival at day 14. The secondary outcome was the proportion of patients discharged from hospital to home/rehabilitation on day 14. Adverse events were abstracted from electronic health records. ResultsAmong the 267 patients included in the analysis, 96 were assigned to the treatment group. Median age was 86, interquartile range 83 to 90 and 95% had a SARS-CoV-2 PCR-confirmed diagnosis. Use of corticosteroids was significantly associated with an increased survival (weighted hazard ratio [wHR] 0.66, 95% CI 0.44 to 0.97). There was no significant difference between the treatment and control groups regarding the proportion of patients discharged to home/rehabilitation at day 14 (wRR 1.11, 95% CI 0.68 to 1.81). Twenty-two (16.7%) patients receiving corticosteroids developed adverse events while only 11 (6.4%) from the control group did. ConclusionsCorticosteroids were associated with a significant increase the day-14 overall survival of patients over 80 years old hospitalized for severe COVID-19. Impact statementWe certify that this work is novel. As of today, studies on the efficacy of corticosteroids did not specifically target elderly patients. Among older patients aged over 80 years old, the RECOVERY trial found no difference in the survival of patients treated or not with dexamethasone. However, the heterogeneity in the severity of infection within the latter subgroup limited the drawing of strong conclusions
Matching journals
The top 14 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Corticosteroids in COVID-19: Optimizing Observational Research through Target Trial Emulations 91%
- Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial 91%
- Self-reported Memory Problems Eight Months after Non-Hospitalized COVID-19 in a Large Cohort 90%
Similar papers in this journal
- Hydroxychloroquine For The Treatment Of Severe Respiratory Infection By COVID-19: A Randomized Controlled Trial 94%
- Safety and effectiveness of RBD-specific polyclonal equine F(ab′)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: a retrospective cohort study 93%
- Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis 93%
Similar papers in this journal
- Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19 94%
- The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial 93%
- Rehabilitation needs and mortality associated with the Covid-19 pandemic: a population-based study of all hospitalised and home-healthcare individuals in a Swedish healthcare region 91%
Similar papers in this journal
- Predictors of adverse outcome in patients with suspected COVID-19 managed in a ‘virtual hospital’ setting: a cohort study 92%
- Quality of Life in elderly ICU survivors:A Rapid Systematic Review and Meta-Analysis of Cohort Studies. 92%
- Effects of 12 weeks of Multi-nutrient supplementation on the Immune and Musculoskeletal systems of Older Adults in Aged-Care (The Pomerium Study): Protocol for a Randomised Controlled Trial 91%
Similar papers in this journal
- Early Short Course Corticosteroids in Hospitalized Patients with COVID-19 92%
- Real-World Effectiveness Of Nirmatrelvir/Ritonavir On COVID-19-Associated Hospitalization Prevention: A Population-Based Cohort Study In The Province Of Québec, Canada 91%
- A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.